170 related articles for article (PubMed ID: 34298646)
41. Distinct Metabolic Signatures of Hormone-Sensitive and Castration-Resistant Prostate Cancer Revealed by a
Zheng H; Zhu Y; Shao X; Cai A; Dong B; Xue W; Gao H
J Proteome Res; 2020 Sep; 19(9):3741-3749. PubMed ID: 32702989
[TBL] [Abstract][Full Text] [Related]
42. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
[TBL] [Abstract][Full Text] [Related]
43. Down-regulation of
Soerohardjo I; Widodo I; Heriyanto DS; Zulfiqqar A; Anwar SL
Ann Med Surg (Lond); 2020 Dec; 60():549-554. PubMed ID: 33299560
[TBL] [Abstract][Full Text] [Related]
44. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
[TBL] [Abstract][Full Text] [Related]
45. AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy.
Winther MD; Kristensen G; Stroomberg HV; Berg KD; Toft BG; Brooks JD; Brasso K; Røder MA
Diagnostics (Basel); 2020 Jul; 10(8):. PubMed ID: 32726925
[TBL] [Abstract][Full Text] [Related]
46. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
Fizazi K; Smith MR; Tombal B
Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
[TBL] [Abstract][Full Text] [Related]
47. Targeting ADT-Induced Activation of the E3 Ubiquitin Ligase Siah2 to Delay the Occurrence of Castration-Resistant Prostate Cancer.
Yan T; Zhou D; Shi Y; Cui D; Jiang J; Han B; Xia S; Wang Z; Liu H; Guo W; Jing Y
Front Oncol; 2021; 11():637040. PubMed ID: 33937036
[TBL] [Abstract][Full Text] [Related]
48. Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy.
Shibata Y; Suzuki K; Arai S; Miyoshi Y; Umemoto S; Masumori N; Kamiya N; Ichikawa T; Kitagawa Y; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Kubota Y
Andrology; 2013 May; 1(3):505-11. PubMed ID: 23444052
[TBL] [Abstract][Full Text] [Related]
49. The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway.
Wang L; Song G; Chang X; Tan W; Pan J; Zhu X; Liu Z; Qi M; Yu J; Han B
Oncogene; 2015 Sep; 34(36):4735-45. PubMed ID: 25500540
[TBL] [Abstract][Full Text] [Related]
50. Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications.
Pisano C; Tucci M; Di Stefano RF; Turco F; Scagliotti GV; Di Maio M; Buttigliero C
Crit Rev Oncol Hematol; 2021 Jan; 157():103185. PubMed ID: 33341506
[TBL] [Abstract][Full Text] [Related]
51. Senescence and castration resistance in prostate cancer: A review of experimental evidence and clinical implications.
Carpenter VJ; Patel BB; Autorino R; Smith SC; Gewirtz DA; Saleh T
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188424. PubMed ID: 32956765
[TBL] [Abstract][Full Text] [Related]
52. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
Anantharaman A; Small EJ
Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
[TBL] [Abstract][Full Text] [Related]
53. [Availability of Local Therapy to Castration-Resistant Prostate Cancer for M0 Patients with Initial Prostate Specific Antigen 100 ng/ml or Higher].
Kuromoto A; Tanaka T; Koyama J; Goto T; Kimura S; Katsumata Y; Myoen S; Ozawa M; Morozumi K; Sato M; Hoshi S; Numahata K; Arai Y
Hinyokika Kiyo; 2017 Dec; 63(12):515-520. PubMed ID: 29370662
[TBL] [Abstract][Full Text] [Related]
54. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
[TBL] [Abstract][Full Text] [Related]
55. Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer.
Miller ET; Chamie K; Kwan L; Lewis MS; Knudsen BS; Garraway IP
Cancer Med; 2017 Jan; 6(1):163-172. PubMed ID: 27997745
[TBL] [Abstract][Full Text] [Related]
56. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
[TBL] [Abstract][Full Text] [Related]
57. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
Fujimoto N
J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
[TBL] [Abstract][Full Text] [Related]
58. Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling.
Huang SH; Tseng JC; Lin CY; Kuo YY; Wang BJ; Kao YH; Muller CJF; Joubert E; Chuu CP
Phytomedicine; 2019 Nov; 64():153068. PubMed ID: 31419729
[TBL] [Abstract][Full Text] [Related]
59. Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer.
Matsumoto T; Hatakeyama S; Yoneyama T; Tobisawa Y; Ishibashi Y; Yamamoto H; Yoneyama T; Hashimoto Y; Ito H; Nishimura SI; Ohyama C
Sci Rep; 2019 Nov; 9(1):16761. PubMed ID: 31727974
[TBL] [Abstract][Full Text] [Related]
60. Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer.
Shiota M; Yokomizo A; Fujimoto N; Naito S
Curr Cancer Drug Targets; 2011 Sep; 11(7):870-81. PubMed ID: 21762076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]